WordNet
- a substance (an atom or molecule or radical or ion) that forms a complex around a central atom
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 骨粗鬆症に対するデノスマブ denosumab for osteoporosis
- 2. IL - 1、IL - 6、およびRANKLを抑制する生物学的製剤の関節リウマチ
におけるランダム化臨床試験 randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit il 1 il 6 and rankl - 3. 骨格の正常な発達および骨形成ならびに骨吸収の調節 normal skeletal development and regulation of bone formation and resorption
- 4. 骨転移の機序 mechanisms of bone metastases
- 5. 悪性腫瘍の高カルシウム血症 hypercalcemia of malignancy
English Journal
- Expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin are associated with middle ear cholesteatoma risk.
- Chen AP1, Wang B, Zhong F, Song GZ, Song HF, Yu K, Wang HB, Jiang ZH.
- Acta oto-laryngologica.Acta Otolaryngol.2015 Jul;135(7):655-66. doi: 10.3109/00016489.2015.1011789. Epub 2015 Mar 26.
- CONCLUSION: Overexpression of receptor activator of nuclear factor-κB ligand (RANKL) and low expression of osteoprotegerin (OPG) are typical features in middle ear cholesteatoma patients. The altered RANKL/OPG protein ratio suggests that alterations in the RANKL-OPG pathway may be major factors in
- PMID 25812671
- The functions of the avian receptor activator of NF-κB ligand (RANKL) and its receptors, RANK and osteoprotegerin, are evolutionarily conserved.
- Sutton KM1, Hu T1, Wu Z1, Siklodi B2, Vervelde L3, Kaiser P1.
- Developmental and comparative immunology.Dev Comp Immunol.2015 Jul;51(1):170-84. doi: 10.1016/j.dci.2015.03.006. Epub 2015 Mar 18.
- A new member of the chicken TNF superfamily has recently been identified, namely receptor activator of NF-κB ligand (RANKL), as have its signalling receptor, RANK, and its decoy receptor, osteoprotegerin (OPG). In mammals, RANKL and RANK are transmembrane proteins expressed on the surface of Th1 ce
- PMID 25796577
- Beneficial effects of tripterygium glycosides tablet on biomarkers in patients with ankylosing spondylitis.
- Ji W1, Chen Y1, Zhao X1, Guo Y1, Zhong L1, Li H2, Wang D3, Song Y4.
- Molecular medicine reports.Mol Med Rep.2015 Jul;12(1):684-90. doi: 10.3892/mmr.2015.3448. Epub 2015 Mar 6.
- The aim of the current study was to explore the effects and possible mechanisms of tripterygium glycosides tablet (TGT) in the treatment of active ankylosing spondylitis (AS). Thirty‑six patients with active AS were given a 20 mg TGT treatment three times per day for 12 weeks, and 21 unrelated
- PMID 25760304
Japanese Journal
- Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression
- Goto Hisataka,Osaki Makoto,Fukushima Tatsuya,Sakamoto Kazutaka,Hozumi Akira,Baba Hideo,Shindo Hiroyuki
- Biomedical Research 32(1), 37-44, 2011-02
- … The TNF-family molecule, Receptor Activator of Nuclear factor κ B Ligand (RANKL) is known as a key regulator for bone remodeling, and is essential for the development and activation of osteoclasts. … RANKL expression and the RANKL/osteoprotegerin (OPG) mRNA ratio in marrow adipocytes increased following dexamethasone treatment. …
- NAID 120003037548
Related Links
- Understanding the science of bone biology. ... changed the understanding of bone biology. Amgen researchers W. Scott Simonet, David Lacey, and William J. Boyle published the first description of osteoprotegerin in a 1997 Cell paper ...
- In just 3 years, striking new advances have been made in understanding the molecular mechanisms that govern the crosstalk between osteoblasts/stromal cells and hemopoietic osteoclast precursor cells that leads to osteoclastogenesis. Led first by the discovery of osteoprotegerin (OPG), a naturally ...
Related Pictures
★リンクテーブル★
| リンク元 | 「osteoclast differentiation factor」「破骨細胞分化抑制因子リガンド」 |
| 関連記事 | 「osteoprotegerin」 |
「osteoclast differentiation factor」
「破骨細胞分化抑制因子リガンド」
「osteoprotegerin」
- 同
- OPG